Diarrhoea News and Research

RSS

Cholera toxin binds differently to intestinal cells than previously thought

The likelihood of becoming seriously ill from cholera depends on your blood group. It is possible to find a new remedy for the feared illness by studying the molecular structure in the toxin in the cholera bacteria.

28 Aug 2012

Children more likely to pick up stomach infections from private water supplies

Children drinking from around half the UK's private water supplies are almost five times more likely to pick up stomach infections - according to research from the University of East Anglia (UEA).

26 Aug 2012

Herbal plant extract may help cure breast cancer

Scientists at Aston University and Russells Hall Hospital have discovered that an extract from a common plant in Pakistan may help cure breast cancer.

24 Aug 2012

Antibiotics: do they affect contraceptives?

NPS MedicineWise has released information for consumers about taking antibiotics when also using hormonal contraceptives, explaining that there are only two antibiotics that affect how hormonal contraceptives work.

23 Aug 2012

Patients in clinical trials of new targeted cancer therapies appear to have lower risk of side-effects

Patients in early clinical trials of new-style targeted cancer therapies appear to have a much lower risk of the most serious side-effects than with traditional chemotherapy, according to a new analysis.

8 Aug 2012

EC approves Vertex's KALYDECO for treatment of cystic fibrosis

Vertex Pharmaceuticals Incorporated announced today that the European Commission has approved KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

28 Jul 2012

Molecular explanation for increased susceptibility to intestinal inflammation in malnutrition

More than one billion people in poor countries are starving, and malnutrition remains a major problem even in rich countries, making it a leading cause of death in the world. For over a hundred years, doctors have known that a lack of protein in the diet or low levels of amino acids, the building blocks of proteins, can lead to symptoms like diarrhoea, inflamed intestines and other immune system disorders, which weaken the body and can be fatal. However, the molecular mechanism which explains how malnutrition causes such severe symptoms has been largely unexplored.

26 Jul 2012

EC grants Marketing Authorisation to Boehringer Ingelheim and Lilly’s Jentadueto for diabetes

Boehringer Ingelheim and Eli Lilly and Company received Marketing Authorisation from the European Commission for Jentadueto which combines the DPP-4 inhibitor, linagliptin and metformin in a single tablet.

25 Jul 2012

CSIRO to produce antibodies for development of new vaccines against rotavirus

CSIRO has been contracted by PATH (Program for Appropriate Technology in Health) to produce antibodies on a large scale that will aid the development of new, safe, affordable and effective vaccines against rotavirus, a major cause of severe and fatal diarrhoea in young children worldwide.

18 Jul 2012

Astellas submits enzalutamide MAA with EMA for treatment of CRPC

Today, Astellas Pharma Inc. announces the submission of a European marketing authorisation application to the European Medicines Agency (EMA) for enzalutamide for the treatment of men with metastatic castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.

27 Jun 2012

European CHMP adopts positive opinion for teduglutide to treat short bowel syndrome

Takeda Pharmaceutical Company Limited and NPS Pharmaceuticals, Inc., jointly announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product teduglutide (Revestive) as a once-daily treatment for adult patients with short bowel syndrome (SBS).

22 Jun 2012

Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 trial on CP-CML

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL (dasatinib) in Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukaemia (CP-CML) adult patients resistant or intolerant to Glivec (imatinib).

16 Jun 2012

Tackling diarrhea, pneumonia could save 2M children, according to UNICEF report

"Two million of the world's poorest children could be saved by introducing routine vaccination programs against diarrhea and pneumonia," according to a new report (.pdf) from UNICEF, BBC News reports (6/8).

8 Jun 2012

Pneumonia and diarrhoea remain biggest killers of East Asia-Pacific children

A new report from UNICEF has highlighted the huge child survival gap between the richest and the poorest children by focusing on pneumonia and diarrhoea – the two primary killers of children under the age of five.

8 Jun 2012

Pioneering new test can quickly diagnose coeliac disease

Coeliac disease affects millions of people worldwide, but many sufferers are not aware they have the condition or may have been misdiagnosed with other illnesses. A pioneering new test developed with EU-funding should soon be available in hospitals, offering an accurate, quick, cost-effective diagnosis and monitoring solution.

6 Jun 2012

Zinc supplementation in young children with serious infections significantly lowers risk of treatment failure

Treating young children with suspected serious bacterial infection with zinc in addition to standard antibiotics significantly reduces the likelihood of treatment failure, according to new research published Online First in The Lancet. In 2010, worldwide, infections were responsible for nearly two-thirds of deaths in children under 5, with around two-fifths of deaths occurring within the first month of life.

1 Jun 2012

Cabazitaxel offers added benefit for men with metastatic prostate cancer

Cabazitaxel has been approved since March 2011 in men with metastatic prostate cancer who no longer respond to conventional therapy with hormone blockers and have already been pre-treated with the cytostatic drug docetaxel.

30 May 2012

Lilly, Boehringer Ingelheim receive positive opinion from EMA for Jentadueto

Boehringer Ingelheim and Eli Lilly and Company today announced that they have received a positive opinion from the European Medicines Agency's medicinal committee recommending approval of Jentadueto,which combines the DPP-4 inhibitor, linagliptin and metformin in a single tablet. If approved by the European Commission, linagliptin/metformin hydrochloride (HCl) will provide a new, single-tablet treatment option, taken twice-daily, for adults with Type 2 Diabetes who need to improve control of their blood glucose.

28 May 2012

Probiotics may reduce the risk of antibiotic associated diarrhoea

Probiotics are live microorganisms intended to boost health, such as the bacteria in some yogurts. These are popular among the health conscious. One of probiotics' most popular uses is in preventing and treating digestive problems.

9 May 2012

E coli detection in contaminated meat to be ‘sped up’ says USDA

The government is gearing up to speed up the process for tracking E. coli in meat, a move that will help authorities more quickly find the source of bacteria outbreaks and hasten recalls of contaminated food.

3 May 2012